Please suggest Nutritional, lifestyle recommendations for all these cancers for those who are having high genetic predisposed risk Topic : Consumer (en) liverCancer lungCancer lymphoma melanoma meningioma multipleMyeloma neuroblastoma neurofibroma osteosarcoma ovarianCancer pancreaticCancer paraganglioma parathyroidCancer pheochromocytoma pituitaryAdenoma prostateCancer retinoblastoma rhabdomyosarcoma skinBasalCellCancer skinSquamousCellCancer stomachCancer thyroidCancer uterineCancer uvealMelanoma wilmsTumour
nutritional lifestyle recommendations genetic cancer predisposition prevention 2024 2025
cancer prevention diet lifestyle genetic risk
WCRF AICR cancer prevention recommendations diet exercise alcohol weight 2024
hereditary cancer syndrome lifestyle modification prevention review
pheochromocytoma paraganglioma neuroblastoma retinoblastoma rhabdomyosarcoma Wilms tumor lifestyle nutrition prevention genetic predisposition
obesity physical activity cancer risk reduction multiple cancer types
uveal melanoma meningioma multiple myeloma lymphoma osteosarcoma lifestyle diet risk prevention review 2024
Important note: These recommendations do not replace medical care or genetic counseling. Anyone with a confirmed or suspected hereditary cancer syndrome should work with a genetic counselor, oncologist, or specialist in cancer predisposition. The guidance below is designed to complement - not substitute - your clinical surveillance program.
| # | Recommendation | Practical Target |
|---|---|---|
| 1 | Maintain a healthy body weight | BMI 18.5-24.9; avoid weight gain after age 18 |
| 2 | Be physically active | At least 150-300 min moderate aerobic activity/week; limit prolonged sitting |
| 3 | Eat a plant-forward diet | Half your plate: vegetables, fruits, wholegrains, legumes |
| 4 | Limit "fast foods" | Minimize foods high in fat, starch, and salt |
| 5 | Limit red and processed meat | Red meat: <500g cooked/week; processed meat: as little as possible |
| 6 | Limit sugar-sweetened drinks | Drink mostly water, unsweetened tea/coffee |
| 7 | Limit or avoid alcohol | For cancer prevention: zero alcohol is best |
| 8 | Do not use supplements for cancer prevention | Get nutrients from food; high-dose supplements are not proven to prevent cancer and some increase risk |
| 9 | Breastfeed if possible | At least 6 months (reduces maternal breast/ovarian cancer risk) |
| 10 | Do not smoke; avoid tobacco in all forms | Smoking is linked to >12 cancer types |
| Cancer | Top Priority Action | Key Food Focus | Top Avoid |
|---|---|---|---|
| Liver | Zero alcohol; coffee; healthy weight | Mediterranean diet; low iron if HFE | Alcohol; aflatoxin-contaminated food |
| Lung | Stop smoking; radon test | Cruciferous veg; NO beta-carotene supplements if smoker | Tobacco; asbestos; beta-carotene supplements |
| Lymphoma | Avoid pesticides; healthy weight | Plant-based; cruciferous veg; green tea | Pesticides; processed meats; immunosuppressants |
| Melanoma | Sun protection; no tanning beds | Polyphenols; lycopene | UV tanning; unprotected sun exposure |
| Meningioma | Minimize ionizing radiation | Anti-inflammatory; low-fat dairy | Head/neck radiation; progestins (discuss with doctor) |
| Multiple Myeloma | High-fiber plant diet; healthy weight | Cruciferous veg; whole grains; vitamin D | Western diet; benzene/chemical exposure |
| Neuroblastoma | Avoid prenatal pesticides; no smoking in pregnancy | Prenatal Mediterranean diet; folate | Pesticides; tobacco smoke (prenatal) |
| Neurofibroma (NF1) | Anti-inflammatory diet; avoid radiation | Quercetin & resveratrol foods; adequate protein | Radiation; obesity |
| Osteosarcoma | Weight-bearing exercise; avoid radiation | Calcium + vitamin D; omega-3 | Smoking; radiation (TP53/RB1 carriers) |
| Ovarian | Oral contraceptive discussion; breastfeed | Cruciferous veg; folate; omega-3 | Talc; smoking; obesity |
| Pancreatic | No smoking; control blood sugar | Plant-forward; coffee; low-GI | Smoking; obesity; alcohol; diabetes uncontrolled |
| Paraganglioma | Blood pressure monitoring; avoid stimulants | Low-tyramine diet if active | Tyramine foods; stimulants; caffeine excess |
| Parathyroid | Hydration; weight-bearing exercise | Adequate calcium + vitamin D from food | Calcium supplements excess |
| Pheochromocytoma | BP monitoring; avoid stimulants | Low-tyramine diet; anti-inflammatory | Tyramine foods; stimulants; anesthetic triggers |
| Pituitary Adenoma | Stress management; sleep | Low-GI diet; adequate iodine + vitamin D | Smoking; disrupted sleep; chronic stress |
| Prostate | Exercise; healthy weight | Lycopene; cruciferous veg; green tea; soy | High-fat meat; calcium supplement excess |
| Retinoblastoma | Avoid radiation; genetic counseling | Vitamin A; antioxidants; folate | Radiation; smoking (adult RB1 carriers) |
| Rhabdomyosarcoma | Avoid prenatal carcinogens; genetic counseling | Nutrient-dense; protein; folate | Prenatal pesticides/solvents; tobacco |
| Skin BCC | Sun protection; no tanning beds | Nicotinamide (B3); antioxidants | UV tanning; unprotected sun |
| Skin SCC | Sun protection; HPV vaccine | Nicotinamide (B3); vitamin A | UV tanning; immunosuppression; smoking |
| Stomach | H. pylori eradication; reduce salt | Fresh fruit + veg; garlic/onion; green tea | Salt; pickled/smoked foods; smoking; hot beverages |
| Thyroid | Minimize neck radiation; MEN2 surgery discussion | Iodine (balanced); selenium; vitamin D | Radiation; iodine excess or deficiency |
| Uterine | Weight management; exercise | High-fiber; whole grains; cruciferous veg | Obesity; unopposed estrogen; sedentary lifestyle |
| Uveal Melanoma | UV-blocking sunglasses; eye surveillance | Lutein + zeaxanthin; omega-3 | Direct sun to eyes; UV exposure without protection |
| Wilms Tumour | Prenatal pesticide avoidance; renal surveillance | Prenatal folate/omega-3; breastfeeding | Prenatal pesticides; smoking in pregnancy |
what should be the elevated blood parameters and genetic traits for the following condition 1. Diabetes & Insulin Resistance 2. Fatty Liver & Liver Health 3. Obesity & Weight Management 4. Cardiovascular Health 5. Gut & Digestive Health 6. Oral & Dental Health 7. Sleep & Recovery 8. Stress & Mental Wellness 9. Nutrition & Micronutrient Health 10. Sports, Fitness & Injury Risk 11. Women's Health 12. Men's Health
biomarkers genetic variants diabetes obesity cardiovascular fatty liver gut health clinical lab parameters elevated risk 2024 2025
genetic SNPs variants TCF7L2 FTO APOE MTHFR PNPLA3 TM6SF2 HLA health risk biomarkers reference ranges 2024
polygenic risk score metabolic syndrome biomarkers genetic variants clinical parameters
elevated blood biomarkers genetic traits sleep disorder stress cortisol oral health gut microbiome sports injury risk lab parameters
genetic variants sleep disorders cortisol stress biomarkers sports injury predisposition
How to use this guide: Each domain lists (A) Blood/Lab Biomarkers - the specific parameters that, when elevated (or suppressed), signal increased risk or active dysfunction, with reference thresholds; and (B) Genetic Traits / SNPs - the key gene variants associated with predisposition to that condition. Both columns together form the basis for precision health risk stratification.
| Biomarker | Concern Threshold | Clinical Significance |
|---|---|---|
| Fasting Plasma Glucose (FPG) | ≥5.6 mmol/L (100 mg/dL) = prediabetes; ≥7.0 mmol/L (126 mg/dL) = diabetes | Primary diagnostic marker |
| HbA1c (Glycated Haemoglobin) | 5.7-6.4% = prediabetes; ≥6.5% = diabetes | 3-month average blood glucose |
| 2-hour Post-Load Glucose (OGTT) | ≥7.8 mmol/L = impaired glucose tolerance; ≥11.1 mmol/L = diabetes | Tests glucose clearance capacity |
| Fasting Insulin | >15-20 µIU/mL (lab-specific) | Elevated with insulin resistance even when glucose is normal |
| HOMA-IR (calculated) | >2.5 = insulin resistance; >5.0 = significant | Fasting insulin × fasting glucose ÷ 22.5 |
| C-Peptide | Elevated in type 2 (hyperinsulinism); low in type 1 | Distinguishes type 1 vs. type 2 |
| Triglycerides | ≥1.7 mmol/L (150 mg/dL) | Dyslipidaemia of insulin resistance |
| HDL Cholesterol | <1.0 mmol/L (40 mg/dL) men; <1.3 mmol/L (50 mg/dL) women | Low HDL is part of metabolic syndrome |
| hs-CRP | >3.0 mg/L | Chronic low-grade inflammation drives beta-cell destruction |
| Adiponectin | <6 µg/mL (low is worse) | Inversely associated with insulin resistance |
| Uric Acid | >6 mg/dL (women); >7 mg/dL (men) | Marker of metabolic syndrome, fructose overload |
| Ferritin | >200 ng/mL (women); >300 ng/mL (men) | Iron overload impairs insulin signalling |
| Gene | Variant | Effect |
|---|---|---|
| TCF7L2 | rs7903146 (T allele) | Strongest T2D genetic risk; impairs GLP-1-mediated insulin secretion |
| FTO | rs9939609 (A allele) | Associated with obesity and T2D risk; influences appetite regulation |
| PPARG | Pro12Ala (rs1801282) | Pro12Pro increases T2D risk; reduces insulin sensitivity |
| KCNJ11 | E23K (rs5219) | Impairs pancreatic beta-cell potassium channel function; reduces insulin secretion |
| SLC30A8 | rs13266634 | Zinc transporter in beta cells; risk allele reduces insulin storage |
| GCKR | rs780094 | Glucokinase regulator; risk allele dysregulates hepatic glucose/lipid metabolism |
| HHEX / IDE | rs1111875 | Affects beta-cell development and insulin degradation |
| HNF1A / HNF4A | MODY1/MODY3 mutations | Monogenic maturity-onset diabetes of the young |
| IRS1 | rs2943641 | Insulin receptor substrate; risk allele reduces insulin signalling |
| MC4R | rs17782313 | Melanocortin receptor; obesity-driven T2D risk |
| Biomarker | Concern Threshold | Clinical Significance |
|---|---|---|
| ALT (Alanine Aminotransferase) | >35 U/L (women); >40 U/L (men) | Most sensitive marker of hepatocyte injury |
| AST (Aspartate Aminotransferase) | >40 U/L | Elevated in liver damage; AST:ALT >2:1 suggests alcoholic liver disease |
| GGT (Gamma-Glutamyl Transferase) | >50 U/L | Sensitive to alcohol exposure and liver fat accumulation |
| ALP (Alkaline Phosphatase) | >120 U/L (adult) | Elevated in cholestatic liver disease |
| Total Bilirubin | >17 µmol/L (>1.0 mg/dL) | Reflects impaired bilirubin metabolism / liver function |
| Albumin | <35 g/L (low is worse) | Marker of hepatic synthetic function; falls in cirrhosis |
| Ferritin | >200 µg/L (women); >300 µg/L (men) | Elevated in NAFLD/MAFLD; also haemochromatosis |
| Triglycerides | ≥1.7 mmol/L | Key driver of hepatic steatosis |
| Fasting Insulin / HOMA-IR | >2.5 | Insulin resistance drives hepatic fat accumulation |
| FIB-4 Index (calculated) | >1.3 = intermediate risk; >2.67 = high fibrosis risk | Uses age, ALT, AST, platelet count to stage fibrosis |
| Platelet Count | <150 × 10⁹/L (falling trend) | Falling platelets indicate progressive fibrosis / portal hypertension |
| AFP (Alpha-Fetoprotein) | >20 ng/mL (surveillance context) | Screening marker for hepatocellular carcinoma in cirrhosis |
| Gene | Variant | Effect |
|---|---|---|
| PNPLA3 | rs738409 (G allele / I148M) | Strongest genetic risk for NAFLD, NASH, and cirrhosis; impairs triglyceride hydrolysis |
| TM6SF2 | rs58542926 (T allele / E167K) | Reduces VLDL secretion; promotes hepatic lipid retention and fibrosis |
| MBOAT7 | rs641738 (T allele) | Alters phospholipid remodelling; increases inflammation and fibrosis risk |
| GCKR | rs780094 (T allele) | Dysregulates hepatic glucose/lipid flux; combined dysglycaemia and steatosis |
| HFE | C282Y, H63D | Haemochromatosis; iron overload-driven liver damage |
| SERPINA1 | PiZ allele (rs28929474) | Alpha-1 antitrypsin deficiency; progressive liver disease |
| APOE | ε4 allele | Less efficient lipid clearance; higher hepatic fat accumulation risk |
| NCAN | rs2228603 | Neurocan variant; associated with NAFLD and liver fat |
| ATP7B | Various mutations | Wilson disease; copper accumulation-driven liver disease |
| Biomarker | Concern Threshold | Clinical Significance |
|---|---|---|
| BMI (anthropometric) | ≥25 = overweight; ≥30 = obese | Primary clinical screen; waist circumference adds precision |
| Fasting Insulin / HOMA-IR | >2.5 | Insulin resistance precedes and perpetuates obesity |
| Triglycerides | ≥1.7 mmol/L | Central adiposity biomarker |
| HDL Cholesterol | Low (<1.0 men / <1.3 women mmol/L) | Inversely related to visceral fat |
| Leptin | >10 ng/mL (men); >20 ng/mL (women) - elevated | Leptin resistance accompanies obesity |
| Adiponectin | <6 µg/mL (low) | Anti-inflammatory adipokine; falls with obesity |
| hs-CRP | >3.0 mg/L | Adipose tissue is an inflammatory organ |
| Uric Acid | >7 mg/dL (men); >6 mg/dL (women) | Elevated in visceral obesity |
| TSH (Thyroid Stimulating Hormone) | >4.5 mIU/L | Subclinical hypothyroidism causes weight gain |
| Cortisol (morning serum or salivary) | >550 nmol/L (morning) or abnormal diurnal pattern | Hypercortisolism (Cushing's or chronic stress) drives central obesity |
| Total Testosterone (men) | <10 nmol/L | Low testosterone associated with visceral fat accumulation |
| Gene | Variant | Effect |
|---|---|---|
| FTO | rs9939609 (A allele) | Most replicated obesity SNP; increases energy intake via appetite dysregulation |
| MC4R | rs17782313 (C allele) | Melanocortin-4 receptor; monogenic and polygenic obesity |
| LEP / LEPR | Various | Leptin and leptin receptor mutations; extreme early-onset obesity |
| TMEM18 | rs6548238 | Transcription regulatory gene; strong obesity association |
| GNPDA2 | rs10938397 | Glucosamine-6-phosphate deaminase; associated with BMI |
| BDNF | rs6265 (Val66Met) | Brain-derived neurotrophic factor; appetite regulation |
| UCP1 / UCP2 / UCP3 | Various | Uncoupling proteins; reduced thermogenesis in brown fat |
| ADRB2 / ADRB3 | Arg16Gly; Trp64Arg | Adrenergic receptor variants; reduced fat mobilisation |
| PCSK1 | Various | Prohormone convertase; rare monogenic obesity via impaired satiety |
| Biomarker | Concern Threshold | Clinical Significance |
|---|---|---|
| LDL Cholesterol | >3.0 mmol/L (general); >1.8 mmol/L (very high-risk) | Primary atherogenic lipoprotein |
| Total Cholesterol | >5.0 mmol/L | General cardiovascular screening threshold |
| HDL Cholesterol | <1.0 mmol/L (men); <1.2 mmol/L (women) | Protective; low HDL is independent CVD risk factor |
| Triglycerides | ≥1.7 mmol/L (borderline); ≥5.6 mmol/L (severe) | Hypertriglyceridaemia increases CVD risk and pancreatitis risk |
| Non-HDL Cholesterol | >3.8 mmol/L | Captures all atherogenic particles (LDL + VLDL + IDL) |
| Lipoprotein(a) [Lp(a)] | >50 mg/dL (or >125 nmol/L) | Independent, largely genetic CVD risk factor; not lowered by statins |
| ApoB (Apolipoprotein B) | >100 mg/dL | More accurate than LDL for atherogenic particle burden |
| hs-CRP | >2.0 mg/L (intermediate risk); >3.0 mg/L (high risk) | Vascular inflammation |
| Homocysteine | >15 µmol/L | Promotes endothelial damage; linked to MTHFR variants |
| BNP / NT-proBNP | BNP >100 pg/mL; NT-proBNP >300 pg/mL | Heart failure and cardiac stress marker |
| Troponin I or T | Any elevation above 99th percentile | Myocardial injury marker |
| Fibrinogen | >4.5 g/L | Pro-thrombotic; inflammatory cardiovascular risk marker |
| Blood Pressure | ≥130/80 mmHg (stage 1); ≥140/90 mmHg (stage 2) | Hypertension is the leading modifiable CVD risk factor |
| Gene | Variant | Effect |
|---|---|---|
| APOE | ε4 allele | Impaired LDL clearance; higher LDL and CVD risk; also Alzheimer's risk |
| LDLR | >1,700 known mutations | Familial hypercholesterolaemia (FH); severely elevated LDL |
| APOB | R3500Q and others | FH-type elevation; impaired LDL receptor binding |
| PCSK9 | Gain-of-function (D374Y) | FH type 3; increased LDL receptor degradation |
| MTHFR | C677T (rs1801133); A1298C | Elevated homocysteine due to impaired folate metabolism |
| LPA | rs10455872; rs3798220 | Genetically elevated Lp(a); major independent CVD risk |
| F5 | Factor V Leiden (R506Q) | Thrombophilia; deep vein thrombosis, PE risk |
| F2 | Prothrombin G20210A (rs1799963) | Elevated prothrombin; thromboembolism risk |
| 9p21 locus | rs10757278 | Most replicated coronary artery disease (CAD) GWAS locus |
| CETP | rs708272 | Cholesteryl ester transfer protein; affects HDL levels |
| APOA5 | rs662799 | Raised triglycerides |
| VKORC1 / CYP2C9 | Various | Warfarin sensitivity; affects anticoagulation dosing |
| Biomarker | Concern Threshold | Clinical Significance |
|---|---|---|
| Calprotectin (faecal) | >50 µg/g (borderline); >200 µg/g (active inflammation) | Marker of intestinal inflammation (IBD vs. IBS differentiation) |
| hs-CRP | >5 mg/L | Systemic inflammation from gut barrier dysfunction ("leaky gut") |
| ESR (Erythrocyte Sedimentation Rate) | >20 mm/hr (women); >15 mm/hr (men) | Non-specific inflammation; elevated in IBD, coeliac disease |
| Haemoglobin | <120 g/L (women); <130 g/L (men) | Anaemia from malabsorption (iron, B12, folate deficiency) |
| Serum Iron + TIBC + Ferritin | Iron low + high TIBC + low ferritin | Iron deficiency from malabsorption (coeliac, IBD) |
| Vitamin B12 | <148 pmol/L (<200 pg/mL) | Deficiency from gastric atrophy, pernicious anaemia, malabsorption |
| Folate (serum/RBC) | <3 ng/mL | Malabsorption, IBD, coeliac disease |
| Albumin | <35 g/L | Protein malnutrition from gut disease |
| Anti-tTG IgA (tissue transglutaminase) | Any positive titre | Coeliac disease screening |
| Total IgA | Must be checked alongside anti-tTG (IgA deficiency gives false negative) | |
| Zonulin (blood or stool) | Elevated above normal range | Marker of intestinal permeability ("leaky gut") - emerging test |
| ASCA / pANCA | Positive | Crohn's (ASCA+) vs. ulcerative colitis (pANCA+) differentiation |
| Gene | Variant | Effect |
|---|---|---|
| HLA-DQ2 / HLA-DQ8 | DQ2.5 (DQA105/DQB102); DQ8 | Coeliac disease - >95% of cases carry one of these haplotypes |
| NOD2 / CARD15 | R702W, G908R, 1007fs | Crohn's disease susceptibility; impaired bacterial pattern recognition |
| IL23R | rs11209026 (R381Q protective) | IBD, ankylosing spondylitis risk |
| ATG16L1 | rs2241880 (T300A) | Autophagy gene; Crohn's disease risk |
| IRGM | rs13361189 | Autophagy; Crohn's disease |
| SLC22A5 (OCTN2) | Various | Organic cation transporter; Crohn's disease |
| FUT2 | rs601338 (non-secretor status) | Affects gut microbiome composition (Bifidobacterium levels); norovirus susceptibility |
| LCT | rs4988235 (C allele) | Lactase non-persistence; lactose intolerance |
| ABCB1 (MDR1) | C3435T | Drug efflux pump; IBD susceptibility and drug response |
| Biomarker | Concern Threshold | Clinical Significance |
|---|---|---|
| HbA1c / Fasting Glucose | ≥5.7% / ≥5.6 mmol/L | Poor glycaemic control worsens periodontitis; bidirectional relationship |
| hs-CRP | >3 mg/L | Periodontal disease is an independent source of systemic inflammation |
| IL-6 (Interleukin-6) | >3.1 pg/mL | Elevated in active periodontal disease; systemic inflammatory spillover |
| WBC (White Blood Cell Count) | >11 × 10⁹/L | Infection / inflammatory response to oral pathogens |
| Vitamin D (25-OH-D) | <50 nmol/L (<20 ng/mL) | Vitamin D deficiency impairs immune response and bone mineralisation in the jaw |
| Calcium | <2.2 mmol/L | Low calcium increases risk of dental bone loss |
| Phosphorus | <0.8 mmol/L | Phosphate deficiency impairs enamel mineralisation |
| PTH (Parathyroid Hormone) | >65 pg/mL | Secondary hyperparathyroidism causes jaw bone demineralisation |
| Salivary IgA | Reduced levels | Lower salivary IgA = impaired mucosal immunity; more oral pathogens |
| Cortisol (salivary) | Elevated morning cortisol | Chronic stress promotes gingival inflammation via immune suppression |
| Gene | Variant | Effect |
|---|---|---|
| IL-1A / IL-1B | rs1800587; rs1143634 (+3954) | Elevated IL-1 production; increased periodontitis severity |
| TNF-α | rs1800629 (-308G/A) | Higher TNF production; worse periodontal inflammation |
| IL-6 | rs1800795 (-174G/C) | Higher IL-6; aggressive periodontal disease |
| VDR (Vitamin D Receptor) | BsmI, TaqI, FokI, ApaI variants | Affects vitamin D signalling in gingival tissues; caries and periodontitis risk |
| DEFB1 | rs1800972; rs1047031 | Beta-defensin (antimicrobial peptide); lower expression = more oral infection risk |
| MMP-1 / MMP-3 | rs1799750; rs3025058 | Matrix metalloproteinases; tissue degradation in periodontitis |
| CTLA-4 | rs231775 | Immune regulation; associated with aggressive periodontitis |
| eNOS | rs1799983 (Glu298Asp) | Nitric oxide; gingival blood flow and periodontal tissue health |
| FBN1 | Various | Marfan syndrome; dental/palatal arch abnormalities |
| Biomarker | Concern Threshold | Clinical Significance |
|---|---|---|
| Cortisol (evening salivary or serum) | >5 nmol/L (salivary PM); flattened diurnal curve | Loss of normal cortisol decline = poor sleep architecture |
| Melatonin (urine 6-sulphatoxymelatonin overnight) | Low output | Suppressed melatonin = circadian misalignment, insomnia |
| TSH (Thyroid Stimulating Hormone) | >4.5 mIU/L or <0.4 mIU/L | Both hypo- and hyperthyroidism severely disrupt sleep |
| Ferritin | <30 ng/mL | Iron deficiency causes restless leg syndrome (RLS) |
| HbA1c / Fasting Glucose | Elevated (prediabetes range) | Blood glucose instability causes nocturnal awakenings |
| Magnesium (RBC or serum) | <0.75 mmol/L (serum) | Deficiency causes muscle cramps, restlessness, poor deep sleep |
| Vitamin D | <50 nmol/L | Low vitamin D associated with increased obstructive sleep apnoea severity and insomnia |
| hs-CRP | >3 mg/L | Inflammation disrupts sleep architecture (IL-6 inhibits restorative slow-wave sleep) |
| IL-6 | >3.1 pg/mL | Elevated in sleep deprivation and sleep apnoea |
| Testosterone (men) | <10 nmol/L total | Low testosterone associated with sleep apnoea and non-restorative sleep |
| IGF-1 | Below age-adjusted reference | Growth hormone (peak in slow-wave sleep) deficiency manifests as non-restorative sleep |
| Gene | Variant | Effect |
|---|---|---|
| CLOCK | rs1801260 (T3111C) | Circadian clock gene; T allele associated with evening chronotype and insomnia |
| PER2 | Various | Period gene mutations cause familial advanced sleep phase syndrome (FASPS) |
| PER3 | rs57875989 (VNTR 4/5 repeat) | 5-repeat allele linked to morning chronotype and sleep homeostasis |
| CRY1 | rs200072668 | Delayed sleep phase disorder (DSPD); cryptochrome 1 mutation |
| ADORA2A | rs5751876 (1976T>C) | Adenosine receptor; caffeine sensitivity and sleep pressure |
| MTNR1B | rs10830963 (G allele) | Melatonin receptor 1B; delayed glucose clearance and circadian disruption |
| DEC2 (BHLHE41) | P384R mutation | "Short sleeper" gene; natural short sleep phenotype |
| ABCC9 | rs11046205 | Potassium channel; associated with sleep duration in GWAS |
| COMT | Val158Met (rs4680) | Dopamine clearance; affects sleep quality and arousal |
| Biomarker | Concern Threshold | Clinical Significance |
|---|---|---|
| Cortisol (AM serum) | >550-600 nmol/L (8am) or flattened diurnal rhythm | HPA axis hyperactivation; chronic psychological stress |
| DHEA-S (Dehydroepiandrosterone Sulphate) | Low for age (varies) | Counter-regulatory to cortisol; low DHEA-S:cortisol ratio = burnout, chronic stress |
| hs-CRP | >3 mg/L | Neuroinflammation links to depression, anxiety |
| IL-6 | >3.1 pg/mL | Inflammatory cytokine; elevated in major depressive disorder |
| Homocysteine | >15 µmol/L | Elevated in depression; neurotoxic; linked to MTHFR variants |
| Vitamin D (25-OH-D) | <50 nmol/L | Low vitamin D strongly associated with depression, anxiety |
| TSH / Free T3 / Free T4 | Thyroid dysfunction | Both hypothyroidism (depression) and hyperthyroidism (anxiety) mimic mental illness |
| Serum B12 | <148 pmol/L | Low B12 linked to depression, fatigue, cognitive decline |
| Folate (RBC) | <3 ng/mL | Deficiency impairs monoamine synthesis; depression risk |
| Zinc (serum) | <70 µg/dL | Low zinc associated with depression; affects NMDA receptor function |
| Magnesium | <0.75 mmol/L | Deficiency promotes HPA axis hyperreactivity and anxiety |
| Omega-3 Index (EPA + DHA) | <4% of RBC fatty acids | Low omega-3 associated with depression and mood disorders |
| Gene | Variant | Effect |
|---|---|---|
| SLC6A4 (5-HTTLPR) | Short (s) allele | Serotonin transporter; s/s genotype increases anxiety and depression risk, especially after adversity |
| COMT | Val158Met (rs4680) | Val/Val = faster dopamine clearance = higher stress reactivity; Met/Met = slower clearance |
| BDNF | Val66Met (rs6265) | Met allele reduces BDNF secretion; higher risk of depression and anxiety |
| MTHFR | C677T (rs1801133) | Impaired folate/methylation; elevated homocysteine; depression risk |
| TPH2 | rs4570625 | Tryptophan hydroxylase 2; serotonin synthesis; mood disorders |
| DRD4 | 7-repeat allele (rs1800955) | Dopamine receptor D4; ADHD, novelty-seeking, stress sensitivity |
| FKBP5 | rs1360780; rs3800373 | FK506-binding protein 5; glucocorticoid receptor sensitivity; PTSD risk |
| CRHR1 | rs110402; rs242924 | Corticotropin-releasing hormone receptor; stress response regulation |
| MAOA | Low-activity variants (uVNTR) | Monoamine oxidase A; linked to impulsivity and aggression under stress (X-linked) |
| NR3C1 | Various | Glucocorticoid receptor gene; cortisol sensitivity variants |
| Biomarker | Concern Threshold | Clinical Significance |
|---|---|---|
| Vitamin D (25-OH-D) | <50 nmol/L = deficiency; <75 nmol/L = insufficiency | Most common micronutrient deficiency globally |
| Vitamin B12 | <148 pmol/L (deficiency); <220 pmol/L (insufficiency) | Neurological and haematological consequences |
| Folate (serum) | <3 ng/mL (serum); <140 ng/mL (RBC folate more reliable) | Neural tube defects, macrocytic anaemia, depression |
| Ferritin | <15 ng/mL (deficiency); <30 ng/mL (functional deficiency) | Iron storage; low in anaemia |
| Serum Iron | <10 µmol/L | Absolute iron deficiency |
| Transferrin Saturation | <16% | Early functional iron deficiency |
| Haemoglobin | <120 g/L (women); <130 g/L (men) | Anaemia |
| Magnesium (serum) | <0.75 mmol/L | Over 300 enzymatic reactions require magnesium |
| Zinc (serum) | <70 µg/dL | Immune function, wound healing, taste, smell, fertility |
| Iodine (urinary) | <100 µg/L (population median) | Thyroid hormone synthesis; cognitive development |
| Selenium (serum) | <60 µg/L | Antioxidant enzyme cofactor; thyroid health |
| Vitamin A (retinol) | <0.7 µmol/L | Night blindness, immune impairment |
| Vitamin C (plasma) | <23 µmol/L | Scurvy range; below 50 µmol/L = insufficiency |
| Omega-3 Index | <4% (deficient); optimal >8% | EPA + DHA as % of RBC fatty acids |
| Homocysteine | >15 µmol/L | B12/B6/folate-responsive; methylation efficiency marker |
| Gene | Variant | Effect |
|---|---|---|
| MTHFR | C677T (rs1801133); A1298C (rs1801131) | Impaired folate metabolism; elevated homocysteine; need more dietary folate or methylated forms |
| VDR | BsmI, TaqI, FokI | Vitamin D receptor variants; require higher vitamin D intake to achieve sufficiency |
| GC (VDBP) | rs2282679; rs7041 | Vitamin D-binding protein; affects 25-OH-D transport and serum levels |
| BCMO1 (BCO1) | rs7501331; rs12934922 | Beta-carotene conversion enzyme; poor converters need preformed vitamin A |
| TMPRSS6 | rs855791 (rs4820268) | Matriptase-2; regulates hepcidin; risk of iron-refractory iron deficiency anaemia (IRIDA) |
| SLC23A1/A2 | Various | Vitamin C transporters; affect tissue vitamin C levels |
| FADS1 / FADS2 | rs174537; rs174575 | Fatty acid desaturase; affects conversion of ALA to EPA/DHA (omega-3 conversion) |
| FUT2 | rs601338 | Non-secretors have lower serum B12 despite adequate intake |
| TCN2 | rs1801198 | Transcobalamin 2; B12 transport into cells; functional B12 deficiency |
| SLC19A1 | rs1051266 | Folate transporter; affects cellular folate uptake |
| Biomarker | Concern Threshold | Clinical Significance |
|---|---|---|
| Creatine Kinase (CK) | >500 U/L (post-exercise baseline >200 = concerning) | Muscle damage marker; very elevated suggests rhabdomyolysis |
| Myoglobin | >80 µg/L | Muscle breakdown; rhabdomyolysis risk marker |
| Lactate Dehydrogenase (LDH) | >250 U/L | Muscle and tissue damage; overtraining marker |
| Ferritin | <30 ng/mL | Iron deficiency is the most common nutritional issue in athletes; impairs aerobic capacity |
| Haemoglobin | <120 g/L (women); <130 g/L (men) | Sports anaemia; reduces VO₂max |
| Vitamin D (25-OH-D) | <50 nmol/L | Strong association with stress fracture risk and muscle function |
| Testosterone (men) | <10 nmol/L | Low testosterone = reduced muscle mass, recovery, and bone density |
| Cortisol | High morning cortisol + low testosterone:cortisol ratio | Overtraining syndrome; catabolism exceeds anabolism |
| IL-6 / hs-CRP | Chronically elevated IL-6 >3.1 pg/mL; CRP >3 mg/L | Persistent inflammation despite rest = injury risk |
| IGF-1 | Low for age | Reduced growth hormone-mediated recovery and muscle protein synthesis |
| Urea / BUN | >7 mmol/L (athletes) | High protein catabolism; dehydration or overtraining |
| Magnesium | <0.75 mmol/L | Muscle cramping, fatigue, impaired nerve conduction |
| Bone-specific ALP / P1NP / CTx | CTx elevated >0.6 ng/mL | Bone resorption markers; elevated risk of stress fractures |
| Gene | Variant | Effect |
|---|---|---|
| ACTN3 | R577X (rs1815739) - XX genotype | Alpha-actinin-3 deficiency; less explosive power; more endurance-adapted (but higher soft tissue injury risk) |
| ACE | I/D polymorphism (rs4646994) | DD = higher ACE activity, better for power/strength; II = better endurance |
| COL5A1 | rs12722 (C/T) | Type V collagen; TT genotype = higher risk of ligament and tendon injuries (ACL, Achilles) |
| COL1A1 | rs1107946; Sp1 binding site | Type I collagen; Sp1 TT genotype = lower collagen density = stress fracture and ligament injury risk |
| MMP3 | rs679620 | Matrix metalloproteinase; tendon and ligament integrity |
| IGF1 | rs35767 | Insulin-like growth factor; muscle mass and recovery capacity |
| VEGFA | rs2010963 | Vascular endothelial growth factor; capillarisation and aerobic adaptations |
| PPARA | rs4253778 (G allele) | Peroxisome proliferator-activated receptor alpha; fat oxidation during endurance |
| AMPD1 | Q12X (rs17602729) | Myoadenylate deaminase deficiency; exercise-induced myalgia and cramps |
| GDF5 | rs143384 (T allele) | Growth differentiation factor 5; Achilles tendinopathy and OA risk |
| NOS3 (eNOS) | rs2070744; rs1799983 | Nitric oxide synthase; vascular response to exercise and blood flow |
| Biomarker | Concern Threshold | Clinical Significance |
|---|---|---|
| FSH (Follicle Stimulating Hormone) | >10 IU/L (early follicular phase) = reduced ovarian reserve; >25 IU/L = perimenopause; >40 IU/L = menopause | Ovarian reserve / menopausal status |
| AMH (Anti-Müllerian Hormone) | <1.0 ng/mL (low ovarian reserve); varies by age | Best marker of ovarian reserve; independent of cycle day |
| LH (Luteinising Hormone) | LH:FSH ratio >2:1 | Characteristic of PCOS |
| Total Testosterone | >2.5 nmol/L (women) | Hyperandrogenaemia; PCOS |
| Free Testosterone / FAI | Elevated free androgen index | PCOS, CAH, adrenal tumours |
| SHBG (Sex Hormone Binding Globulin) | <30 nmol/L (low in PCOS) | Low SHBG = more free androgens |
| Oestradiol (E2) | <100 pmol/L (reproductive age, follicular) = concern | Low oestrogen: premature ovarian insufficiency, hypothalamic amenorrhoea |
| Progesterone (day 21) | <16 nmol/L | Anovulation or luteal phase deficiency |
| Prolactin | >600 mIU/L (without pregnancy) | Hyperprolactinaemia causes amenorrhoea and galactorrhoea |
| TSH / Free T4 / TPO antibodies | TSH >4.5 mIU/L; TPO-Ab positive | Autoimmune thyroiditis (Hashimoto's) is very common in women; causes irregular cycles |
| 25-OH Vitamin D | <50 nmol/L | Deficiency linked to PCOS, endometriosis, fertility issues |
| Ferritin / Haemoglobin | <15 ng/mL ferritin; <120 g/L Hb | Menorrhagia-related iron deficiency anaemia |
| CA-125 | >35 U/mL | Ovarian cancer and endometriosis marker (low specificity) |
| BRCA mutation-specific risk assessment | Genetic testing result | Not a blood level but triggers enhanced surveillance |
| Gene | Variant | Effect |
|---|---|---|
| BRCA1 / BRCA2 | Pathogenic variants | Breast cancer (50-70% lifetime) and ovarian cancer (15-44%) risk |
| CYP1A1 / CYP1B1 | Various | Oestrogen metabolism; influences breast cancer and endometriosis risk |
| ESR1 / ESR2 | rs2234693; rs9340799 | Oestrogen receptor; affects response to hormone therapy, bone density, CVD |
| COMT | Val158Met | Catechol-O-methyltransferase; oestrogen detoxification; breast cancer and PMS risk |
| MTHFR | C677T | Folate/methylation; neural tube defect risk in offspring; gestational complications |
| HLA-DQ2/DQ8 | As above | Associated with autoimmune thyroiditis and coeliac disease (both more common in women) |
| TNF-α | rs1800629 | Endometriosis and dysmenorrhoea susceptibility |
| GDF9 / BMP15 | Various | Oocyte growth factors; premature ovarian insufficiency risk |
| FMR1 | Premutation (55-200 CGG repeats) | Fragile X premutation; primary ovarian insufficiency (FXPOI) |
| DENND1A | rs2479106 | PCOS susceptibility locus |
| THADA | rs13405728 | PCOS susceptibility |
| LHCGR | rs13405728 | LH/hCG receptor; PCOS and ovarian hyperstimulation syndrome risk |
| Biomarker | Concern Threshold | Clinical Significance |
|---|---|---|
| Total Testosterone | <10 nmol/L (<300 ng/dL) = hypogonadism | Primary male sex hormone; affects muscle, bone, libido, mood, cognition |
| Free Testosterone | <225 pmol/L (<65 pg/mL) | More biologically active fraction; better indicator than total T |
| LH / FSH | LH and FSH elevated with low T = primary hypogonadism | Distinguish primary (testicular) vs. secondary (pituitary) hypogonadism |
| SHBG | >60 nmol/L (high in older men) | High SHBG binds testosterone; leaves less free T despite normal total T |
| Oestradiol (E2) | >180 pmol/L (men) | Elevated oestrogen in obese men (aromatase); gynecomastia, low libido |
| PSA (Prostate Specific Antigen) | >4 ng/mL (or rising PSA velocity >0.75 ng/mL/year) | Prostate cancer and BPH screening |
| DHT (Dihydrotestosterone) | Low DHT = impaired 5-alpha reductase activity | Benign prostatic hyperplasia risk when elevated |
| Haematocrit / Haemoglobin | >54% haematocrit | Polycythaemia (natural or iatrogenic with testosterone therapy) |
| Sperm Parameters (semen analysis) | Count <15 million/mL; motility <32%; morphology <4% normal | Male fertility assessment |
| FSH (men) | >7.6 IU/L | Impaired spermatogenesis |
| Inhibin B | <80 pg/mL (men) | Low inhibin B = Sertoli cell dysfunction; impaired sperm production |
| Prolactin | >500 mIU/L | Prolactinoma; causes low testosterone and erectile dysfunction |
| hs-CRP / IL-6 | Elevated | Inflammation suppresses Leydig cell testosterone production |
| HbA1c / Insulin / HOMA-IR | Elevated | Metabolic syndrome is the leading cause of hypogonadism in men |
| Gene | Variant | Effect |
|---|---|---|
| AR (Androgen Receptor) | CAG repeat length (>26 = reduced sensitivity) | Longer CAG repeats = androgen insensitivity; affects testosterone action in tissues |
| SRD5A2 | V89L (rs523349); A49T | 5-alpha reductase type 2; affects DHT production; prostate cancer risk |
| CYP17A1 | rs743572 | Androgen synthesis; testosterone and prostate cancer risk |
| BRCA2 | Pathogenic variants | ~8-fold increased risk of prostate cancer; also male breast cancer |
| HOXB13 | G84E (rs138213197) | Hereditary prostate cancer; strong association in northern European ancestry |
| SLC45A3 | Various | Prostate-specific gene; prostate cancer susceptibility |
| SHBG | rs727428; rs6259 | Genetic determinants of SHBG levels; affects free testosterone |
| GHR | d3 variant (exon 3 deletion) | Growth hormone receptor; affects IGF-1 response and body composition |
| KAL1 / FGFR1 / GNRHR | Various | Kallmann syndrome and idiopathic hypogonadotrophic hypogonadism |
| CFTR | ΔF508 and others | Cystic fibrosis; congenital bilateral absence of vas deferens (CBAVD) in carriers - azoospermia |
| AZF loci (Y chromosome) | AZFa, AZFb, AZFc deletions | Azoospermia factor; primary cause of non-obstructive azoospermia and infertility |
| Domain | Critical Blood Markers to Elevate Concern | Top Genetic Variants |
|---|---|---|
| Diabetes | HbA1c ≥5.7%; FPG ≥5.6 mmol/L; HOMA-IR >2.5 | TCF7L2, FTO, PPARG, KCNJ11 |
| Fatty Liver | ALT >35-40 U/L; Ferritin >300 (men); Triglycerides ≥1.7 | PNPLA3 I148M, TM6SF2 E167K, MBOAT7, HFE |
| Obesity | HOMA-IR >2.5; Triglycerides ≥1.7; Low HDL; Leptin elevated | FTO, MC4R, LEP/LEPR, UCP variants |
| Cardiovascular | LDL >3.0 mmol/L; Lp(a) >50 mg/dL; Homocysteine >15; hs-CRP >3 | APOE ε4, LDLR, MTHFR C677T, LPA, Factor V Leiden |
| Gut Health | Faecal Calprotectin >200; Low B12/Ferritin/Folate; Anti-tTG IgA+ | HLA-DQ2/DQ8, NOD2, ATG16L1, FUT2, LCT |
| Oral Health | HbA1c ≥5.7%; Vitamin D <50 nmol/L; hs-CRP >3 | IL-1B +3954, TNF-α -308, VDR variants, DEFB1 |
| Sleep | PM Cortisol elevated; Ferritin <30; TSH abnormal; Low Magnesium | CLOCK rs1801260, PER2/3, CRY1, ADORA2A |
| Stress/Mental | AM Cortisol >550 nmol/L; Low DHEA-S; Homocysteine >15; Low B12/D | 5-HTTLPR s allele, COMT Val158Met, BDNF Val66Met, MTHFR, FKBP5 |
| Nutrition | Vit D <50 nmol/L; B12 <148 pmol/L; Ferritin <15; Omega-3 Index <4% | MTHFR, VDR, BCMO1, FADS1/2, FUT2, TMPRSS6 |
| Sports/Fitness | CK >500 U/L; Ferritin <30; Vit D <50; Low T:cortisol ratio | ACTN3 R577X, ACE I/D, COL5A1, COL1A1, AMPD1 |
| Women's Health | FSH >10 IU/L; AMH <1.0 ng/mL; LH:FSH >2:1; TPO antibodies + | BRCA1/2, COMT, MTHFR, FMR1 premutation, DENND1A |
| Men's Health | Testosterone <10 nmol/L; PSA >4 ng/mL; LH/FSH elevated; Prolactin >500 | AR CAG repeats, BRCA2, HOXB13, AZF deletions, CFTR |
14. Environmental Longevity & Toxic Load 15. Healthy Ageing & Longevity Thyroid Vitamin D Calcium Iron Vitamin B12
environmental toxic load biomarkers heavy metals oxidative stress genetic susceptibility CYP450 GST NAT polymorphisms 2024 2025
healthy ageing longevity biomarkers telomere length IGF-1 SIRT1 FOXO3 klotho mTOR genetic traits 2024 2025
thyroid autoimmunity genetic variants TPO antibodies TSH HLA
longevity biomarkers genetic variants aging telomere oxidative stress inflammation
thyroid disease genetic variants HLA TPO TSHR SLC26A4 FOXE1 calcium metabolism PTH CYP27B1 VDR iron absorption HFE hepcidin vitamin B12 IF intrinsic factor genetic risk 2024
environmental toxin load biomarkers blood urine heavy metals BPA POPs oxidative stress 8-OHdG malondialdehyde genetic detox CYP1A2 GSTM1 GSTT1 NAT2 health risk 2025
| Biomarker | Concern Threshold | What It Indicates |
|---|---|---|
| Blood Lead (Pb) | >5 µg/dL (children); >10 µg/dL (adults, occupational) | Neurotoxicity, hypertension, renal damage; no safe level exists |
| Blood Mercury (Hg) | >5 µg/L (total); >3.5 µg/L (methylmercury) | Neurotoxicity, autoimmune disruption, renal damage |
| Urinary Arsenic (As) | >35 µg/g creatinine (total inorganic) | Carcinogen; skin, lung, bladder cancer risk; neuropathy |
| Urinary Cadmium (Cd) | >0.5 µg/g creatinine | Renal tubular damage (Fanconi syndrome); osteoporosis; lung cancer |
| Serum/Urinary Bisphenol-A (BPA) | Any detectable level is common; elevated >2 µg/g creatinine | Endocrine disruptor; thyroid, reproductive, metabolic disruption |
| Urinary Phthalates (DEHP metabolites) | Elevated above population median (NHANES reference) | Endocrine disruption; testosterone suppression; asthma risk |
| POPs / PCBs / Organochlorines (serum) | Any elevated level vs. population reference | Accumulate in fat; linked to cancer, thyroid dysfunction, diabetes |
| Urinary Glyphosate | >0.3 µg/L (concern threshold varies) | Herbicide; disrupts gut microbiome; oxidative stress |
| 8-OHdG (8-hydroxy-2'-deoxyguanosine - urine) | >15 ng/mg creatinine | DNA oxidative damage marker; elevated with heavy metal and toxin load |
| Malondialdehyde (MDA - plasma) | >2 µmol/L | Lipid peroxidation product; marker of oxidative stress from toxin exposure |
| Oxidised LDL (ox-LDL) | >60 U/L | Vascular oxidative damage; POPs and heavy metals promote LDL oxidation |
| hs-CRP | >3 mg/L | Systemic inflammation driven by toxin-induced oxidative stress |
| Serum Glutathione (GSH) | <600 µmol/L (whole blood) | Depleted glutathione = impaired toxin conjugation and excretion |
| Gamma-Glutamyl Transferase (GGT) | >50 U/L | Sensitive early marker of hepatic toxic load; elevated by alcohol, solvents, metals |
| ALT / AST | >40 U/L | Hepatocellular damage from solvent, metal, or mycotoxin exposure |
| Urinary Creatinine-corrected Mycotoxins | Detectable elevated levels (aflatoxin, ochratoxin A, trichothecenes) | Carcinogenic; renal, hepatic, and immune toxicity |
| Serum Vitamin C | <23 µmol/L | Antioxidant depletion under heavy toxic load |
| Urinary Organic Acids | Elevated quinolinic acid, kynurenic acid | Tryptophan pathway disruption by toxins; neurotoxic downstream effects |
| Gene | Variant | Effect on Toxic Load |
|---|---|---|
| CYP1A1 | rs4646903 (MspI); rs1048943 (Ile462Val) | Phase I enzyme; Ile/Val increases carcinogen bioactivation (PAHs, dioxins); higher cancer risk with smoke/pollution exposure |
| CYP1A2 | rs762551 (C allele = slow metaboliser) | Slower caffeine/aromatic amine metabolism; higher carcinogen exposure duration |
| CYP1B1 | rs1056836 (Val432Leu) | Oestrogen and PAH metabolism; risk of hormone-sensitive cancers with toxin exposure |
| GSTM1 | Null deletion (GSTM1*0) | No functional GSMT1; impaired glutathione conjugation of heavy metals, benzene, and aflatoxin - 2-3x increased cancer risk with combined chemical exposure |
| GSTT1 | Null deletion (GSTT1*0) | No GSTT1; impaired removal of peroxides, ethylene oxide; compounded risk when combined with GSTM1 null |
| GSTP1 | Ile105Val (rs1695) | Reduced GSTP1 activity; less effective clearance of PAHs and chemotherapy agents |
| NAT2 | Slow acetylator haplotypes (rs1799929, rs1799930, rs1208) | Impaired phase II N-acetylation of aromatic amines (found in tobacco smoke, well-done meats); elevated carcinogen retention |
| NQO1 | C609T (rs1800566) - Pro187Ser | NADPH quinone oxidoreductase 1; reduced benzene detoxification; leukaemia risk with benzene exposure |
| MTHFR | C677T (rs1801133) | Impaired methylation; reduced capacity to detoxify arsenic (methylation is the primary arsenic excretion route) |
| MT1A / MT2A (Metallothioneins) | Various promoter variants | Metallothioneins bind and sequester cadmium, lead, zinc; low expression = more metal toxicity |
| SOD2 (MnSOD) | Val16Ala (rs4880) | Mitochondrial superoxide dismutase; Ala/Ala form less efficiently imported; higher mitochondrial oxidative stress with toxin exposure |
| CAT (Catalase) | rs1001179 (C/T) | Catalase breaks down hydrogen peroxide; low-activity variant = more oxidative DNA damage |
| GPX1 | Pro198Leu (rs1050450) | Glutathione peroxidase 1; Leu allele = lower antioxidant enzyme activity; more lipid peroxidation |
| ABCB1 (MDR1/P-gp) | C3435T (rs1045642); G2677T | Multi-drug resistance protein; low-function variants = reduced toxin efflux from cells; higher intracellular accumulation |
| ABCC2 (MRP2) | Various | Hepatic export of conjugated toxins into bile; reduced function = accumulation of bilirubin, drugs, and conjugated xenobiotics |
| HMOX1 | (GT)n repeat length in promoter | Haem oxygenase 1; long repeats = lower HMOX1 induction; less cytoprotection under heavy metal stress |
| Biomarker | Concern Direction | Clinical Significance |
|---|---|---|
| Telomere Length (leukocyte, T/S ratio) | Shorter than age-adjusted reference | Shorter telomeres = more cell senescence; associated with CVD, cancer, dementia, and all-cause mortality |
| Epigenetic Clock Age (Horvath/GrimAge/PhenoAge) | Biological age > chronological age by >3-5 years | DNA methylation-based age; accelerated ageing phenotype |
| IL-6 (Interleukin-6) | >3.1 pg/mL | "Inflammaging" - chronic low-grade inflammation is the central driver of accelerated ageing |
| IL-18 | >200 pg/mL | Inflammasome activation; strongly associated with frailty and accelerated ageing |
| TNF-α | >8.1 pg/mL | Pro-inflammatory cytokine; elevated in frailty syndrome and sarcopenia |
| hs-CRP | >3 mg/L | Low-grade inflammatory tone; independently predicts longevity gap |
| IGF-1 (Insulin-like Growth Factor 1) | Low for age (below lower quartile) OR very high (>300 ng/mL in elderly) | Low IGF-1 in later life = frailty; very high IGF-1 = cancer promotion. Optimal "Goldilocks" range in mid-life |
| Insulin / HOMA-IR | HOMA-IR >2.5 | Insulin resistance is one of the strongest predictors of biological age acceleration |
| HbA1c | ≥5.7% | Chronic hyperglycaemia causes advanced glycation end-products (AGEs) that cross-link proteins and accelerate ageing |
| Fasting Triglycerides | ≥1.7 mmol/L | Atherogenic dyslipidaemia; accelerated vascular ageing |
| LDL Cholesterol | >3.0 mmol/L (persistent) | Cardiovascular ageing |
| Homocysteine | >12 µmol/L | Vascular and neural toxicity; independently predicts cognitive decline and cardiovascular ageing |
| Klotho (serum alpha-Klotho) | <400 pg/mL (older adults) | Klotho is the "anti-ageing hormone"; low levels associated with frailty, CVD, and cognitive decline |
| DHEA-S | Low for age (progressive decline) | Adrenal reserve marker; low DHEA-S = accelerated immunosenescence and muscle loss |
| GDF-11 / GDF-15 | GDF-15 >1200 pg/mL | Elevated GDF-15 = cellular stress, mitochondrial dysfunction; strong frailty and mortality predictor |
| Senescence-Associated Secretory Phenotype (SASP) markers | IL-6, IL-8, MMP-3 elevated together | Reflects accumulation of senescent cells; drives tissue dysfunction |
| Vitamin D (25-OH-D) | <50 nmol/L | Low vitamin D is consistently associated with accelerated biological ageing |
| NAD+ levels (blood) | Declining with age (>40 years) - no single cutoff yet | NAD+ depletion impairs sirtuins, mitochondrial function, and DNA repair |
| Albumin | <38 g/L (older adults) | Falling albumin in absence of liver/kidney disease = nutritional ageing; strong longevity predictor |
| Lymphocyte Count | <1.5 × 10⁹/L | Immunosenescence; reduced immune surveillance |
| Mean Platelet Volume (MPV) | >12 fL | Platelet activation; marker of pro-thrombotic ageing state |
| eGFR (kidney function) | <60 mL/min/1.73m² | Kidney function is one of the most powerful predictors of lifespan |
| Gene | Variant | Effect on Ageing / Longevity |
|---|---|---|
| FOXO3 | rs2802292 (G allele) | Most consistently replicated human longevity SNP; G allele overrepresented in centenarians across multiple populations; activates stress resistance, autophagy, and DNA repair pathways; protects telomere length in older adults |
| APOE | ε2 allele (longevity protective); ε4 allele (longevity risk) | APOE ε2 is enriched in centenarians; ε4 increases Alzheimer's risk and cardiovascular mortality |
| CETP | rs5882 (I405V) | Cholesterol ester transfer protein; I405V variant associated with higher HDL and extended lifespan in Ashkenazi Jewish centenarian study |
| SIRT1 / SIRT3 / SIRT6 | Various regulatory variants | Sirtuins are NAD+-dependent deacetylases; regulate DNA repair, mitochondrial biogenesis, inflammation suppression; SIRT6 directly regulates telomere maintenance |
| TERT / TERC | rs7726159 (TERT); rs10936599 (TERC) | Telomerase components; variants affecting telomerase activity determine baseline telomere maintenance rate |
| mTOR / RPTOR | Various | mTOR pathway is the central nutrient-sensing and ageing regulator; reduced mTOR signalling extends lifespan across species |
| IGF1R | Various loss-of-function variants | Reduced IGF-1 receptor signalling is associated with longevity in multiple species; centenarians show enrichment for IGF1R variants |
| KLOTHO | rs9536314 (KL-VS haplotype, heterozygous advantage) | Klotho FG variant heterozygotes show better cognitive function and cardiovascular protection in later life |
| TP53 | rs1042522 (Arg72Pro) | p53 tumour suppressor; Pro/Pro = better cancer suppression but possibly less longevity; complex trade-off |
| CDKN2A (p16/p21) | rs2811712 and 9p21 locus | Cell cycle arrest and senescence regulation; variants affect rate of cellular senescence accumulation |
| HLA complex | Various haplotypes | Immune system diversity; broader HLA repertoire associated with better immune resilience into old age |
| LMNA | Mutations (progeroid syndromes) | Lamin A/C; progerin accumulation causes Hutchinson-Gilford progeria (rapid ageing); subclinical variants may accelerate normal ageing |
| BRCA1 / BRCA2 | Pathogenic variants | Impaired DNA repair accelerates genomic instability - a hallmark of ageing |
| PPARGC1A (PGC-1α) | Gly482Ser (rs8192678) | Mitochondrial biogenesis regulator; Ser variant = lower mitochondrial density; accelerated metabolic ageing |
| NRF2 (NFE2L2) | rs6721961; rs35652124 | Master antioxidant transcription factor; low-activity variants = weaker antioxidant response to cellular stress |
| Hallmark | Key Measurable Biomarker |
|---|---|
| Genomic instability | 8-OHdG (urine); gamma-H2AX (blood) |
| Telomere attrition | Leukocyte telomere length (T/S ratio) |
| Epigenetic alterations | GrimAge / PhenoAge epigenetic clock |
| Loss of proteostasis | Serum heat shock proteins; protein carbonyl levels |
| Disabled macroautophagy | LC3-II / p62 ratio (research context) |
| Deregulated nutrient sensing | Fasting insulin; IGF-1; GDF-15 |
| Mitochondrial dysfunction | Lactate:pyruvate ratio; mitochondrial DNA copy number |
| Cellular senescence | IL-6 + IL-8 + MMP-3 (SASP panel); p16 INK4a expression |
| Stem cell exhaustion | CD34+ progenitor cell counts (declining) |
| Altered intercellular communication | Klotho; GDF-15; growth differentiation factors |
| Chronic inflammation | hs-CRP; IL-6; TNF-α |
| Dysbiosis | Faecal microbiome diversity; serum LPS (lipopolysaccharide) |
| Biomarker | Concern Threshold | Clinical Significance |
|---|---|---|
| TSH (Thyroid Stimulating Hormone) | >4.5 mIU/L = hypothyroidism; <0.4 mIU/L = hyperthyroidism | Primary screening test; most sensitive thyroid function marker |
| Free T4 (fT4) | Low (<12 pmol/L) with high TSH = overt hypothyroidism; High (>22 pmol/L) with low TSH = overt hyperthyroidism | Active thyroxine; reflects hormone production |
| Free T3 (fT3) | Low (<3.5 pmol/L) = hypothyroid symptoms despite normal fT4 | Biologically active form; low fT3 with normal fT4 suggests poor T4-to-T3 conversion (DIO2 variants) |
| Total T4 / Total T3 | Affected by TBG levels (pregnancy, OCP) | Useful when binding protein changes suspected |
| TPO Antibodies (anti-TPO) | >34 IU/mL (positive) | Hashimoto's thyroiditis (autoimmune hypothyroidism); >500 IU/mL = high activity |
| Thyroglobulin Antibodies (anti-TgAb) | >115 IU/mL (positive) | Hashimoto's; also interferes with thyroglobulin monitoring in thyroid cancer |
| TSH Receptor Antibodies (TRAb / TSI) | >1.75 IU/L (stimulating) | Graves' disease (autoimmune hyperthyroidism); also blocking antibodies in some hypothyroidism |
| Thyroglobulin (Tg) | Detectable after total thyroidectomy for thyroid cancer | Thyroid cancer surveillance marker |
| Reverse T3 (rT3) | >24 ng/dL (elevated) | Inactive T3 form; elevated in chronic stress, illness, calorie restriction - "euthyroid sick" |
| fT3:rT3 ratio | <20 (low) | Low ratio = poor T4 activation; functional hypothyroidism even with normal TSH |
| Calcitonin | >10 pg/mL (women); >19 pg/mL (men) | Elevated in medullary thyroid carcinoma (MTC); RET mutation screening |
| Gene | Variant | Effect |
|---|---|---|
| HLA-DR3 (HLA-DRB1*03:01) | HLA-DQ2.5; HLA-DR3/4 | Strongly associated with both Hashimoto's thyroiditis and Graves' disease; immune tolerance disruption |
| PTPN22 | rs2476601 (R620W) | Protein tyrosine phosphatase; major autoimmune risk variant for Graves', Hashimoto's, T1D, RA |
| CTLA-4 | rs231775 (49G/A); rs3087243 | Immune checkpoint; reduced CTLA-4 function = overactive T cells attacking thyroid |
| CD40 | rs1883832 (C/T, -1 Kozak) | B-cell co-stimulator; elevated CD40 expression promotes thyroid autoantibody production |
| TSHR | rs179247; rs2268458; rs12101255 | TSH receptor; variants associated with Graves' disease susceptibility |
| TG (Thyroglobulin gene) | rs4985155; rs653029 | Thyroid autoantigen; variants associated with Hashimoto's thyroiditis |
| TPO | rs11675434; various | Thyroid peroxidase; enzyme variants reduce T4/T3 synthesis efficiency; autoimmunity target |
| DIO2 (Deiodinase type 2) | Thr92Ala (rs225014) | Impaired conversion of T4 → T3 in peripheral tissues; normal TSH/fT4 but low fT3 and persisting hypothyroid symptoms |
| SLC26A4 (Pendrin) | Various (Pendred syndrome) | Iodide transporter; loss of function causes goitre + sensorineural deafness |
| SLC5A5 (NIS) | Various | Sodium-iodide symporter; impaired iodide uptake into thyroid |
| FOXE1 | rs965513; rs1867277 | Thyroid transcription factor; strong Graves' and thyroid cancer susceptibility |
| RET | C634F/R/Y, M918T (MEN2 mutations) | Proto-oncogene; germline mutations cause familial medullary thyroid carcinoma and MEN2 |
| BRAF | V600E (somatic but inherited predisposition via BRAF pathway genes) | Papillary thyroid cancer |
| NR3C1 (Glucocorticoid Receptor) | Various | Cortisol sensitivity; chronic stress via cortisol suppresses TSH and T4-to-T3 conversion |
| Biomarker | Level | Clinical Significance |
|---|---|---|
| 25-OH Vitamin D (25-hydroxyvitamin D) | <30 nmol/L (<12 ng/mL) = severe deficiency | Rickets (children), osteomalacia (adults), high PTH, impaired immunity |
| 30-49 nmol/L (12-19 ng/mL) = deficiency | Bone loss, muscle weakness, infection susceptibility | |
| 50-74 nmol/L (20-29 ng/mL) = insufficiency | Sub-optimal; increased fracture risk, impaired immune regulation | |
| 75-150 nmol/L (30-60 ng/mL) = sufficiency | Optimal range for most health outcomes | |
| >250 nmol/L (>100 ng/mL) = toxicity risk | Hypercalcaemia, nephrocalcinosis | |
| PTH (Parathyroid Hormone) | >65 pg/mL (secondary hyperparathyroidism) | Elevated PTH is the physiological response to low vitamin D; causes bone resorption |
| Calcium (serum) | Low (<2.2 mmol/L) in severe vitamin D deficiency | Hypocalcaemia from impaired gut calcium absorption |
| Phosphate | Low (<0.8 mmol/L) in rickets/osteomalacia | Phosphate wasting from elevated PTH |
| ALP (Alkaline Phosphatase) | >120 U/L | Elevated in bone disease associated with vitamin D deficiency |
| Calcium:creatinine ratio (urine) | Low (<0.15) in vitamin D deficiency | Reduced urinary calcium excretion |
| 1,25-(OH)₂ Vitamin D (Calcitriol) | May be normal or elevated even when 25-OH-D is low | Active form; regulated by CYP27B1; testing rarely needed routinely |
| Gene | Variant | Effect |
|---|---|---|
| GC (Vitamin D Binding Protein - VDBP) | rs2282679 (A allele); rs7041 (T allele) | Low-binding protein variants significantly reduce serum 25-OH-D levels; most influential vitamin D level determinant |
| VDR (Vitamin D Receptor) | BsmI (rs1544410); TaqI (rs731236); FokI (rs2228570); ApaI (rs7975232) | Affect VDR function and downstream gene expression; FokI FF genotype = less responsive VDR |
| CYP2R1 | rs10741657 (G allele) | 25-hydroxylase (liver conversion of vitamin D3 → 25-OH-D); G allele reduces 25-OH-D levels |
| CYP27B1 | Various | 1-alpha-hydroxylase (kidney activation to calcitriol); mutations cause vitamin D-dependent rickets type 1 |
| CYP24A1 | Various inactivating mutations | 24-hydroxylase (vitamin D degradation); loss-of-function causes hypercalcaemia with normal/low 25-OH-D (idiopathic infantile hypercalcaemia) |
| DHCR7 | rs12785878 (T allele) | 7-dehydrocholesterol reductase; T allele reduces cutaneous vitamin D synthesis capacity |
| RXRA | Various | Retinoid X receptor alpha; forms heterodimer with VDR; affects vitamin D gene expression |
| Biomarker | Concern Threshold | Clinical Significance |
|---|---|---|
| Serum Total Calcium | <2.15 mmol/L = hypocalcaemia; >2.55 mmol/L = hypercalcaemia | Total calcium affected by albumin levels; correct for albumin |
| Corrected Calcium | <2.15 (corrected) = true hypocalcaemia; >2.55 = true hypercalcaemia | Corrected Ca = Total Ca + 0.02 × (40 - albumin g/L) |
| Ionised Calcium | <1.15 mmol/L = ionised hypocalcaemia; >1.35 mmol/L = ionised hypercalcaemia | Physiologically active fraction; most accurate |
| PTH (Parathyroid Hormone) | Elevated (>65 pg/mL) with normal/high calcium = primary hyperparathyroidism; Elevated with low calcium = secondary HPT | PTH is the primary regulator of calcium homeostasis |
| Vitamin D (25-OH-D) | <50 nmol/L | Primary cause of secondary hyperparathyroidism |
| Phosphate | Inverse relationship to calcium; low phosphate in hyperparathyroidism | PTH promotes renal phosphate wasting |
| ALP | >120 U/L | Bone ALP elevated in bone involvement of calcium disorders |
| Urine Calcium (24-hour) | >7.5 mmol/day (men); >6.25 mmol/day (women) = hypercalciuria | Kidney stone risk; hypercalciuria with hypercalcaemia = primary HPT or hypervitaminosis D |
| Magnesium | <0.75 mmol/L | Hypomagnesaemia impairs PTH secretion; can cause hypocalcaemia resistant to calcium replacement |
| Calcitonin | >19 pg/mL (men); >10 pg/mL (women) | Elevated in medullary thyroid carcinoma; calcitonin lowers calcium |
| PTH-rP (PTH-related peptide) | >2 pmol/L | Elevated in hypercalcaemia of malignancy |
| 1,25-(OH)₂D (Calcitriol) | Elevated with hypercalcaemia in sarcoidosis and granulomatous disease | Ectopic calcitriol production raises calcium |
| Gene | Variant | Effect |
|---|---|---|
| CASR (Calcium-Sensing Receptor) | Activating mutations (hypocalcaemia); Inactivating mutations (hypercalcaemia) | Gain-of-function = autosomal dominant hypocalcaemia; Loss-of-function = familial hypocalciuric hypercalcaemia (FHH) or neonatal severe hyperparathyroidism |
| MEN1 | Various pathogenic mutations | Multiple Endocrine Neoplasia type 1; parathyroid adenomas causing primary hyperparathyroidism |
| RET | C634 variants (MEN2A) | MEN2A; parathyroid hyperplasia and hypercalcaemia alongside medullary thyroid cancer and phaeochromocytoma |
| VDR | BsmI, TaqI, FokI, ApaI | Calcium absorption efficiency; certain haplotypes associated with lower intestinal calcium uptake and osteoporosis risk |
| CYP27B1 | Inactivating variants | Reduced calcitriol synthesis; impaired intestinal calcium absorption |
| SLC34A1 / SLC34A3 | Various | Sodium-phosphate cotransporters; mutations cause hereditary hypophosphataemia or phosphate wasting |
| CDC73 (HRPT2) | Various | Hyperparathyroidism-jaw tumour syndrome; parathyroid carcinoma risk |
| GNA11 / AP2S1 | Various | Calcium-sensing pathway components; germline mutations cause FHH type 2 and type 3 |
| Biomarker | Deficiency Threshold | Excess/Overload Threshold | Clinical Significance |
|---|---|---|---|
| Serum Ferritin | <15 ng/mL (storage depletion); <30 ng/mL (functional deficiency) | >300 ng/mL (men); >200 ng/mL (women) = possible overload | Best single marker of iron stores; acute-phase protein (can be falsely elevated in inflammation) |
| Serum Iron | <10 µmol/L | >30 µmol/L | Circulating iron |
| TIBC (Total Iron Binding Capacity) | >70 µmol/L (elevated = iron deficiency) | <50 µmol/L (low = iron overload or inflammation) | Transferrin capacity; inversely related to iron stores |
| Transferrin Saturation (TS%) | <16% = iron deficiency | >45% = possible haemochromatosis | Serum iron ÷ TIBC × 100; most sensitive for haemochromatosis screening |
| Haemoglobin | <120 g/L (women); <130 g/L (men) | - | Anaemia; iron deficiency is the most common cause |
| MCV (Mean Corpuscular Volume) | <80 fL = microcytic | >100 fL = macrocytic (B12/folate deficiency) | Microcytic anaemia is characteristic of iron deficiency |
| MCH (Mean Corpuscular Haemoglobin) | <27 pg | - | Low in iron deficiency |
| Reticulocyte Haemoglobin Content (CHr) | <28 pg | - | Functional iron deficiency even before anaemia develops |
| Soluble Transferrin Receptor (sTfR) | >1.76 mg/L | - | Elevated in tissue iron deficiency; not affected by inflammation (unlike ferritin) |
| sTfR:log ferritin ratio (TfR-F index) | >2.0 | - | Distinguishes iron deficiency anaemia from anaemia of chronic disease |
| Serum Hepcidin | Low (<4 µg/L) in iron deficiency; High (>40 µg/L) in inflammation/overload | - | Master iron regulator; elevated hepcidin blocks iron absorption and release |
| Zinc Protoporphyrin (ZPP) | >80 µmol/mol haem | - | Iron-deficient erythropoiesis; lead poisoning also elevates ZPP |
| Gene | Variant | Effect |
|---|---|---|
| HFE | C282Y (rs1800562) - homozygous; H63D (rs1799945) | Most common hereditary haemochromatosis; C282Y homozygotes have 80-100% penetrance for iron overload; transferrin saturation >45% + elevated ferritin |
| HFE | C282Y / H63D compound heterozygote | Milder haemochromatosis; variable expression |
| HAMP (Hepcidin) | Various inactivating mutations | Juvenile haemochromatosis (type 2B); severe iron overload in young adults |
| HJV (Hemojuvelin) | Various | Juvenile haemochromatosis (type 2A); most severe form; cardiac iron deposition |
| TFR2 (Transferrin Receptor 2) | Various | HH type 3; adult-onset haemochromatosis |
| SLC40A1 (Ferroportin) | Various (gain or loss of function) | HH type 4; macrophage iron retention vs. classical hepatic iron overload depending on variant type |
| TMPRSS6 | rs855791 (A736V) | Matriptase-2; reduces hepcidin suppression; A736V (minor allele) associated with higher ferritin and better iron levels; other variants cause IRIDA (iron-refractory iron deficiency anaemia) |
| TF (Transferrin) | rs3811647 | Transferrin levels; affects iron transport capacity |
| SLC11A2 (DMT1 / NRAMP2) | Various | Divalent metal transporter; reduced iron absorption variants; hypochromic microcytic anaemia |
| Biomarker | Deficiency Threshold | Concern Direction | Clinical Significance |
|---|---|---|---|
| Serum Vitamin B12 | <148 pmol/L (<200 pg/mL) = deficiency | Low | Neurological damage (subacute combined degeneration), macrocytic anaemia, cognitive impairment |
| 148-220 pmol/L = grey zone / borderline | Low | Functional deficiency may exist despite borderline serum levels; use functional markers | |
| >220 pmol/L = generally sufficient | - | ||
| >900 pmol/L = elevated (possible cause: liver disease, haematological malignancy) | High | Paradoxically high B12 can indicate hepatocellular carcinoma, myeloproliferative disease | |
| Holotranscobalamin (Active B12 / HoloTC) | <35 pmol/L = deficiency | Low | Only the fraction of B12 bound to transcobalamin II enters cells; earliest marker of depleted B12 status |
| Methylmalonic Acid (MMA - serum or urine) | >0.40 µmol/L (serum); >3.6 µmol/mol creatinine (urine) | Elevated | Metabolic marker of functional B12 deficiency; elevated even when serum B12 appears borderline |
| Homocysteine | >15 µmol/L | Elevated | Co-marker of B12 and/or folate deficiency; elevated with either |
| Haemoglobin | <120 g/L (women); <130 g/L (men) | Low | Megaloblastic anaemia from impaired DNA synthesis |
| MCV | >100 fL | Elevated | Macrocytosis from ineffective erythropoiesis |
| Hypersegmented Neutrophils | ≥5 lobes in >5% of neutrophils | Elevated | Classic haematological sign of B12/folate deficiency |
| Serum Folate | <3 ng/mL | Low | B12 and folate deficiency often co-exist and cause identical macrocytic anaemia |
| Intrinsic Factor Antibodies (IFAb) | Positive | Positive | Pernicious anaemia; autoimmune destruction of gastric parietal cells that produce intrinsic factor |
| Gastric Parietal Cell Antibodies | Positive | Positive | Atrophic gastritis; impaired intrinsic factor and acid secretion |
| Gastrin | >100 pg/mL | Elevated | Elevated in atrophic gastritis; stomach acid loss drives hypergastrinaemia |
| Gene | Variant | Effect |
|---|---|---|
| FUT2 (Secretor gene) | rs601338 (nonsecretor: AA genotype) | Non-secretors (20-25% of Europeans) cannot secrete blood group antigens into body fluids including the gut; associated with lower serum B12 levels despite adequate intake and higher risk of pernicious anaemia |
| TCN2 (Transcobalamin II) | rs1801198 (776C>G, Pro259Arg) | Transcobalamin II carries B12 into cells; 776GG genotype = lower functional B12 transport even with normal serum B12 |
| TCN1 (Haptocorrin / Transcobalamin I) | rs526934 | R-binder protein; affects serum B12 levels and binding |
| CUBN (Cubilin) | Various | Ileal B12 absorption receptor (with intrinsic factor); mutations cause Imerslund-Gräsbeck syndrome (B12 malabsorption) |
| AMNN (Amnionless) | Various | Forms functional complex with cubilin for ileal B12 uptake |
| GIF (CBLIF - Intrinsic Factor gene) | Various inactivating mutations | Congenital intrinsic factor deficiency; no intrinsic factor secreted = severe B12 deficiency from early childhood |
| MTHFR | C677T (rs1801133); A1298C | Impaired methylation cycle; depletes methyl-THF needed for remethylation of homocysteine; functionally increases B12 requirement |
| MTR (Methionine Synthase) | A2756G (rs1805087) | Methionine synthase uses B12 as cofactor; G allele may affect enzyme activity |
| MTRR (Methionine Synthase Reductase) | A66G (rs1801394) | Reactivates methionine synthase; GG genotype associated with elevated homocysteine when B12/folate intake is suboptimal |
| PCFT (SLC46A1) | Various | Proton-coupled folate transporter; affects folate uptake alongside B12 in intestinal cells |
| Domain | Critical Lab Marker Direction | Top Genetic Risk Variants |
|---|---|---|
| Environmental / Toxic Load | ↑ Blood lead/mercury/arsenic; ↑ 8-OHdG; ↑ GGT; ↓ GSH | GSTM1/GSTT1 null; CYP1A1 Ile/Val; NAT2 slow; NQO1 609T; SOD2 Val16Ala |
| Healthy Ageing / Longevity | ↓ Telomere length; ↑ IL-6; ↑ GDF-15; ↓ Klotho; ↓ DHEA-S; ↑ Insulin; ↑ Homocysteine | FOXO3 TT (risk); APOE ε4; TERT/TERC variants; NRF2 low-activity; PPARGC1A Ser482 |
| Thyroid | ↑ TSH (hypothyroid); ↓ TSH (hyperthyroid); ↑ TPO-Ab; ↑ TRAb; ↓ fT3 with normal fT4 | DIO2 Thr92Ala; PTPN22 R620W; HLA-DR3; CTLA-4 variants; RET (MTC) |
| Vitamin D | ↓ 25-OH-D (<50 nmol/L); ↑ PTH; ↓ Calcium; ↑ ALP | GC rs2282679; CYP2R1 rs10741657; DHCR7 rs12785878; VDR FokI FF |
| Calcium | ↑ Corrected Ca >2.55 (HPT/malignancy); ↓ Ca <2.15 (hypoparathyroid/D deficiency) | HFE (HPT), CASR mutations, MEN1, VDR variants |
| Iron | ↓ Ferritin <15; ↓ TS% <16% (deficiency); ↑ TS% >45%; ↑ Ferritin >300 (overload) | HFE C282Y (haemochromatosis); TMPRSS6 (iron regulation); HJV/HAMP (juvenile HH) |
| Vitamin B12 | ↓ Serum B12 <148 pmol/L; ↓ HoloTC <35 pmol/L; ↑ MMA; ↑ Homocysteine; ↑ MCV | FUT2 nonsecretor; TCN2 776GG; MTHFR C677T; GIF mutations; CUBN/AMNN |
Clinical Note: For environmental toxin domains, blood and urine measurements of specific metals and organic toxins are available through specialist reference laboratories. Genetic detoxification panels (GSTM1/GSTT1, CYP polymorphisms, NAT2 phenotyping) are offered by several accredited genomics laboratories and provide actionable information for personalised environmental health interventions. Always interpret results alongside clinical presentation and a qualified practitioner.
think as a nutrigenecist and suggest for patient having geneticallyhigh risk of bladder cancer : and change these recommecdations : Maintain high daily fluid intake (≥1.5-2 L water/day) to dilute urinary carcinogens and reduce mucosal contact time Eat a diet rich in cruciferous vegetables (broccoli, cabbage, kale) - isothiocyanates increase urinary carcinogen detoxification Limit processed meats, charred/grilled meats, and food containing nitrosamines Avoid aristolochic acid (found in some traditional herbal weight-loss products) Adequate folate from leafy greens supports DNA repair in BRCA-pathway carriers
bladder cancer nutrigenomics diet genetic risk GSTM1 NAT2 prevention
bladder cancer genetic risk GSTM1 NAT2 NAT1 MTHFR GSTT1 nutrigenomics dietary recommendations fluid intake cruciferous vegetables 2024 2025
bladder cancer diet fluid intake vegetables smoking aromatic amines risk
bladder cancer NAT2 slow acetylator aromatic amines heterocyclic amines diet nutrigenomics folate selenium lycopene green tea prevention personalized 2024
https://www.wcrf.org/wp-content/uploads/2024/10/Bladder-canc…
bladder cancer fluid intake arsenic drinking water selenium folate diet risk
Thinking as a Nutrigenomicist: The original recommendations are population-level advice. Below, each one is rebuilt from the ground up using the specific genetic architecture of bladder cancer risk - primarily GSTM1/GSTT1 null deletions, NAT2 slow acetylator phenotype, NAT1 variants, MTHFR, and TP53 pathway - so the recommendations become mechanistically precise, genotype-targeted, and dosage-intentional.
| Gene | Risk Variant | Mechanism | Estimated Bladder Cancer Contribution |
|---|---|---|---|
| GSTM1 | Null deletion (no gene copy) | Cannot conjugate glutathione to urinary carcinogens (PAHs, epoxides, isothiocyanate metabolites) | ~40% of population carry null; OR ≈ 1.40 for bladder cancer |
| GSTT1 | Null deletion | Cannot detoxify chlorinated water by-products, ethylene oxide, certain nitrosamines | Dual GSTM1+GSTT1 null: OR ≈ 1.48 |
| NAT2 | Slow acetylator haplotypes (rs1799929, rs1799930, rs1208) | Cannot hepatically N-acetylate aromatic amines from tobacco/meat → longer carcinogen half-life in urine | Estimated responsible for 20-46% of all bladder cancers |
| NAT1 | Low-activity variants | Urinary tract O-acetylation of aromatic amines; paradoxically activates carcinogens locally | Modifies NAT2 risk |
| MTHFR | C677T (rs1801133) | Impaired folate cycling → reduced thymidylate synthesis → urothelial DNA instability | Amplifies genomic damage under low-folate conditions |
| TP53 / FGFR3 | Germline or acquired variants | Checkpoint failure; cannot arrest damaged urothelial cells before replication | Core driver of progression from dysplasia to invasive cancer |
| CYP1A1 / CYP1A2 | Ile462Val; rs762551 | Activates aromatic amines to reactive metabolites; slow CYP1A2 = prolonged carcinogen activation | Interacts with NAT2 status multiplicatively |
Maintain high daily fluid intake (≥1.5-2 L water/day) to dilute urinary carcinogens and reduce mucosal contact time
Target ≥2.5 L/day of clean, filtered water - but the source matters critically based on your genotype.
Eat a diet rich in cruciferous vegetables (broccoli, cabbage, kale) - isothiocyanates increase urinary carcinogen detoxification
Eat cruciferous vegetables preferentially RAW or lightly steamed (not boiled), but only if you carry at least one functional GSTM1 or GSTT1 copy. If you are GSTM1/GSTT1 null, supplement this strategy with selenium-rich foods and NRF2-activating compounds.
| Your Genotype | Cruciferous Strategy |
|---|---|
| GSTM1 null | Prioritise raw broccoli sprouts (highest sulforaphane), raw watercress, raw mustard greens; aim ≥5 servings/week; add mustard seed powder to cooked broccoli (provides exogenous myrosinase) |
| GSTM1 present + GSTT1 present | Standard cooked cruciferous vegetables still beneficial; supplement with broccoli sprout extract if convenient |
| GSTT1 null specifically | Prioritise foods that activate NRF2 via alternative pathways: curcumin (turmeric), resveratrol (grapes), quercetin (onions, capers), EGCG (green tea) |
Limit processed meats, charred/grilled meats, and food containing nitrosamines
If you are a NAT2 slow acetylator, the threshold for "safe" heterocyclic amine (HCA) and aromatic amine exposure is substantially lower than population guidance. Apply near-complete avoidance, not just limitation, of high-temperature cooked meats.
| Food / Exposure | Risk Level (NAT2 Slow) | Nutrigenomic Action |
|---|---|---|
| Tobacco smoke | Extreme (synergistic with slow NAT2) | Non-negotiable cessation; passive smoke avoidance |
| Well-done/charred red meat (BBQ, pan-fried) | High | Eliminate or restrict to <1×/month; never charred |
| Processed meats (bacon, salami, hot dogs) | High | Nitrosamines bypass NAT2 pathway; apply independent to NAT2 |
| Rubber, dye occupational exposure | Extreme | Career/workplace risk assessment; PPE mandatory |
| Poultry (white meat, well-done) | Moderate | Prefer moist-heat cooking (poaching, steaming) |
| Grilled fish | Low-Moderate | Lower HCA formation than red meat; acceptable grilled |
Avoid aristolochic acid (found in some traditional herbal weight-loss products)
Absolutely avoid aristolochic acid-containing products - but additionally expand this to a comprehensive "urothelial carcinogen avoidance" protocol tailored to your specific detoxification genotype.
| Carcinogen Class | Source | Genotype Most Vulnerable |
|---|---|---|
| Trihalomethanes (chloroform, bromodichloromethane) | Chlorinated tap water, swimming pools | GSTT1 null |
| Benzene | Petrol fumes, industrial solvents, cigarette smoke | GSTM1 null + GSTT1 null |
| Acrolein | Cooking fumes (overheated oils), tobacco smoke, car exhaust | GSTM1 null |
| Aflatoxin metabolites | Improperly stored grains, nuts | GSTM1 null |
| Styrene, epoxides | Plastics, industrial exposure | GSTT1 null |
Adequate folate from leafy greens supports DNA repair in BRCA-pathway carriers
For MTHFR C677T carriers with bladder cancer predisposition, folate alone is insufficient - you need the full methylation-support triad (methylfolate + methylcobalamin B12 + B6), at specific forms and doses, timed around oxidative stress burden.
| Nutrient | Form to Use | Target Intake | Food Source |
|---|---|---|---|
| Folate | 5-methyltetrahydrofolate (5-MTHF / methylfolate) - NOT folic acid | 400-800 µg DFE from food; supplement as methylfolate if deficient | Asparagus, avocado, edamame, dark leafy greens, lentils |
| Vitamin B12 | Methylcobalamin (not cyanocobalamin) | ≥2.4 µg/day from food; supplement 500-1000 µg methylcobalamin if serum B12 <300 pmol/L | Eggs, sardines, mackerel, beef liver, fortified nutritional yeast |
| Vitamin B6 (P5P) | Pyridoxal-5-phosphate (P5P) is the active form | 1.3-1.7 mg/day from food; supplement as P5P if homocysteine elevated | Chicken, tuna, sunflower seeds, pistachio nuts, banana |
| Riboflavin (B2) | Standard dietary form (FAD/FMN) | ≥1.3 mg/day | B2 is the cofactor for MTHFR itself; TT homozygotes are specifically B2-responsive - riboflavin supplementation (1.6 mg/day) normalises elevated homocysteine in MTHFR TT |
| Original Recommendation | Nutrigenomic Reframe | Key Genotype Driver |
|---|---|---|
| ≥1.5-2 L water/day | ≥2.5 L filtered/clean water/day; test for arsenic; add green tea | GSTT1 null (trihalomethanes); NAT2 slow (urine dilution priority) |
| Cruciferous vegetables | RAW preferentially; broccoli sprouts highest priority; myrosinase preservation; selenium for null carriers | GSTM1 null (stronger benefit from raw ITCs); GSTT1 null (NRF2 activation alternatives) |
| Limit processed/grilled meat | Near-elimination for NAT2 slow acetylators; moist-heat cooking mandatory; marinate before grilling; vitamin C with cured meats | NAT2 slow (aromatic amine retention); NAT1 (local urothelial re-activation) |
| Avoid aristolochic acid | Full urothelial carcinogen avoidance protocol; extend to chlorinated water, benzene, acrolein, styrene | GSTT1 null (chlorinated by-products); GSTM1 null (industrial carcinogens) |
| Folate from leafy greens | Methylfolate (not folic acid) + methylcobalamin B12 + P5P B6 + riboflavin; monitor homocysteine | MTHFR C677T TT genotype (impaired folate metabolism → urothelial DNA instability) |